A Major Expert Reset in Delaware

Litigation attorney Eric Alexander published a blog for Drug & Device Law analyzing the recent Delaware Supreme Court decision in In re Zantac (Ranitidine) Litigation, which reversed a lower court's permissive standard for admitting plaintiffs' general causation expert testimony. Mr. Alexander explains how the ruling reinforces a rigorous application of Rule 702 of the Delaware Uniform Rules of Evidence and underscores the trial judge's gatekeeping role to exclude unreliable specialist opinions, especially when they rely on flawed scientific data. This decision may reduce Delaware's appeal as a plaintiff-friendly venue for ranitidine and similar drug and device litigation, highlighting the continuing challenges plaintiffs face in establishing causation in these cases.

READ: A Major Expert Reset in Delaware